Publications by authors named "A Zlotta"
Background: Historically, Asia had a lower prostate cancer (PCa) incidence and mortality compared with Western countries, but the gap is narrowing. Paradoxically, Asians have been reported to present with more advanced disease though more favorable outcomes. Despite PCa becoming an emerging health priority in East Asia, our knowledge remains limited.
View Article and Find Full Text PDFPurpose: Patients with Ta low-grade (LG) NMIBC rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined.
Materials And Methods: This retrospective study included 521 patients diagnosed with primary TaLG NMIBC (n = 491) or papillary urothelial neoplasm of low malignant potential (n = 30) from 1989 to 2019 at an academic center.
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
Cancer
January 2025
Article Synopsis
- Androgen-deprivation therapy (ADT) is a common treatment for advanced prostate cancer but can lead to significant side effects, prompting guidelines for routine testing to monitor these effects.
- A study analyzed data from older men in Ontario, Canada, revealing that adherence to testing guidelines was notably low, with only 11.9% of patients receiving all recommended tests within the first year of ADT.
- The research highlights a need for further investigation into the factors preventing adherence to these recommendations, as most patients are not adequately monitored for potential treatment-related health issues.
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed.
Objectives: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection.
Methods: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers.
Accurate prediction of recurrence and progression in non-muscle invasive bladder cancer (NMIBC) is essential to inform management and eligibility for clinical trials. Despite substantial interest in developing artificial intelligence (AI) applications in NMIBC, their clinical readiness remains unclear. This systematic review aimed to critically appraise AI studies predicting NMIBC outcomes, and to identify common methodological and reporting pitfalls.
View Article and Find Full Text PDF